Business Wire

LINCOTEK

21.3.2022 14:02:44 CET | Business Wire | Press release

Share
Lincotek Acquires Majority Stake in Highly Automated Forging Facility

Global contract manufacturer Lincotek announced today that it has signed an agreement to acquire a majority stake in Italy-based Pegasus’ medical division. The Alaria family will remain fully involved in the business, with Alberto Alaria taking the position of Managing Director of the new entity.

The move will further strengthen the Medical Division of Lincotek Group , which is continuing its global investment program to respond to ever-more demanding customer requirements in terms of integrated solutions. Through new technologies and automation, the company is addressing the growing interest of the orthopedic device market in an automated forging service, increasing efficiency along the supply chain, setting new standards around quality and reliability and further reducing lead time.

The investment represents an important addition to an already comprehensive set of capabilities that Lincotek Medical has in-house and enhances the company’s competitive edge, adding unique, state-of- the-art capabilities in the forging field.

Established in 2007 in Torino, northern Italy, Pegasus decided in 2019 to expand its innovative forging processes into the medical market. The brand-new facility - with a surface area of around 3,000 sqm - is completely dedicated to orthopedic applications, being ISO 13485 certified and having an ISO 17025 certified internal laboratory. Lincotek’s forging offers a unique level of automation through the manufacturing process ensuring state-of-the-art product quality, total process control and repeatability.

The fully robotized forging line - which allows the manufacture of high-quality forged implantable parts to customer specifications – is the flagship of a complete production service of forged components. Its capabilities are combined with a state-of-the-art, AMS-2750-compliant heat treatment furnace ; automated pickling line and liquid penetrant inspection unit ; laboratory equipment; internal mold manufacturing; robotized deburring and polishing unit; and computerized dimensional control.

Lincotek Medical will therefore offer a new, impressive, high-volume capacity, through single service or fully-integrated solutions to support OEMs with a strategic long-term partnership.

Winfried Schaller, CEO of Lincotek Group commented: “With the acquisition of the majority stake in Pegasus medical division, Lincotek Medical is in a stronger position than ever before to support orthopedic OEMs. By combining this impressive forging service with our existing offering, we are able to help customers stay competitive and get to market even faster. It really is a new world of advanced automation and productivity.”

Speaking for Pegasus, Alberto Alaria, the company’s Managing Director, said: “Pegasus is proud to enter into partnership with Lincotek Group which represents a great opportunity to grow our presence in the forged medical implants market with the offering of high-quality products. The new synergies and product integration that will be generated moves us a step ahead and creates the possibility of further strengthening the cooperation with our valued customers.”

Bringing this full suite of processes in-house, orthopedic OEMs can now rely on a well-established partner, which has broad capabilities and brings together the core competencies of R&D, product design, regulatory affairs, and manufacturing all under one roof, keeping focus on their core competencies.

About Lincotek

Lincotek, headquartered in Rubbiano, Parma - Italy, is a global contract manufacturer for services in niche markets including Industrial Gas Turbines, Aviation and Medical Device applications, as well as a leading manufacturer of industrial coating equipment and one of the most respected producers in the Additive Manufacturing field. The Group is family-owned and has more than 1,300 employees located in 17 production facilities across Europe, North America and Asia.

About Pegasus

Established in Favria, Torino (Italy) in 2007 on a 100,000 sqm site, of which 20,000 is covered, PEGASUS has forging, heat treating, machining and NDT inspection capabilities for the production of forged and rolled components for Industrial and Medical purposes.

For more information, please visit lincotek.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release

Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP

Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release

Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp

KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release

Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen

Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye